Former Alcon Executive Joins TearLab as President & COO
October 01 2013 - 7:00AM
TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the
"Company") today announced the appointment of Seph Jensen as the
Company's President and Chief Operating Officer.
Mr. Jensen has an accomplished history of sales and marketing,
operations and general management success in the ophthalmic
industry. He joins TearLab from his current position as Head of
Surgical Marketing at Alcon Laboratories Inc. ("Alcon"), having
responsibility for more than $1.4 billion in revenue across its
cataract, retina and refractive businesses. His 17 years of
progressive experience at Alcon includes previous roles managing
its full surgical equipment portfolio in the United States, leading
its surgical retina equipment portfolio globally, managing its
pharmaceutical products marketing in Japan and various other
commercial assignments. Mr. Jensen's experience at Alcon
brings an important depth of knowledge of the global ophthalmic
pharma and device space to TearLab's management team.
"Seph is a seasoned leader with a strong track record of
delivering operational excellence and profitable growth," commented
TearLab's CEO, Elias Vamvakas. "I have tremendous confidence
in his ability to help us build our sales infrastructure and
sharpen our execution. Most importantly, he is exceptionally
qualified to help us continue to build a unique and powerful
partnership within the eye care community."
Mr. Jensen said, "TearLab is well-positioned for strong growth
in the large, but still essentially untapped, market for simple,
easy to use and objective point-of-care diagnostics within the eye
care space. I am incredibly energized by this opportunity and look
forward to contributing to the Company's continued success."
About TearLab Corporation
TearLab Corporation (www.tearlab.com) develops and markets
lab-on-a-chip technologies that enable eye care practitioners to
improve standard of care by objectively and quantitatively testing
for disease markers in tears at the point-of-care. The
TearLabĀ® Osmolarity Test, for diagnosing Dry Eye Disease, is the
first assay developed for the award-winning TearLab Osmolarity
System. Headquartered in San Diego, CA, TearLab Corporation's
common shares trade on the NASDAQ Capital Market under the symbol
'TEAR' and on the Toronto Stock Exchange under the symbol
'TLB'.
Forward-Looking Statements
This press release may contain forward-looking
statements. These statements relate to future events and are
subject to risks, uncertainties and assumptions about TearLab.
Examples of forward-looking statements in this press release
include statements regarding the future potential of the TearLab
Osmolarity System and the related impact on our sales. These
statements are only predictions based on our current expectations
and projections about future events. You should not place
undue reliance on these statements. Actual events or results may
differ materially. Many factors may cause our actual results
to differ materially from any forward-looking statement, including
the factors detailed in our filings with the Securities and
Exchange Commission and Canadian securities regulatory authorities,
including but not limited to our annual and quarterly reports on
Forms 10-K and 10-Q. We do not undertake to update any
forward-looking statements.
CONTACT: Stephen Kilmer
(647) 872-4849
skilmer@tearlab.com
Talbots (NYSE:TLB)
Historical Stock Chart
From Jul 2024 to Aug 2024
Talbots (NYSE:TLB)
Historical Stock Chart
From Aug 2023 to Aug 2024